Argos Therapeutics Inc

Type: Company
Name: Argos Therapeutics Inc
First reported Apr 09 2014 - Updated Apr 10 2014 - 2 reports

ISA and Beamex present web seminar on calibrating switches

April 9, 2014 - The International Society of Automation (ISA) and Beamex will co-host a free web seminar on 23 April 2014 that will discuss the purpose and most appropriate methods for calibrating switches.The webinar, which will be held from noon to ... [Published Automation.com - Apr 10 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 4 reports

Argos Therapeutics, Inc. Announces Filing Of Its Annual Report On Form 10-K

(GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission. Help employers find you! Check out all the jobs and ... [Published BioSpace - Apr 08 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

Argos Hits $45M IPO

Submitted by jshamp on Fri, 2014-02-07 16:29Argos Therapeutics has joined the growing ranks of companies bootstrapped by North Carolina Biotechnology Center funding that have gone on to become publicly traded..The Durham company, which explored, then ... [Published North Carolina Biotechnology Center - Apr 05 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 1 reports

Argos Therapeutics Inc added to Russell 2000(R) and 3000(R) Indexes

9:30pm BST Argos Therapeutics Inc:Company has been added to Russell 2000 Index and Russell 3000 Index.Addition is effective as March 31. ... [Published Reuters UK - Mar 31 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Argos Therapeutics, Inc. Reports Fourth Quarter And Year-End 2013 Financial Results

(GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology ... [Published BioSpace - Mar 28 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Square 1 Bank takes off on Nasdaq opener

Durham’s Square 1 Bank (Nasdaq: SQBK) is taking off in its debut on the Nasdaq trading market, raking in $56 million before fees and expenses.The bank, which priced at $18 last night — above the range estimate of $15 and $17 — was trading up nearly 12 ... [Published Triangle Business Journal - Mar 27 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Argos Therapeutics to Present at 21st Annual Future Leaders in the Biotech Industry Conference

(GLOBE NEWSWIRE) -- Argos TherapeuticsA live audio webcast of the presentation can be accessed via the Investors section of the Company's website at www.argostherapeutics.com.About Argos Therapeutics Argos Therapeutics is a biopharmaceutical company focused ... [Published BusinessWeek - Mar 21 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

ARGOS THERAPEUTICS : to Present at Regenerative Medicine and Cancer Immunotherapy Meetings

(GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology ... [Published 4 Traders - Mar 19 2014]
First reported Mar 17 2014 - Updated Mar 18 2014 - 1 reports

Argos Therapeutics, Inc.To Hold Fourth Quarter And Year End 2013 Financial Results Conference Call On Thursday, March 27, 2014

(GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 27, 2014. Argos executive management will host a conference ... [Published BioSpace - Mar 17 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 2 reports

Argos Therapeutics to Hold Fourth Quarter and Year End 2013 Financial Results Conference Call on Thursday, March 27, 2014

(GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 27, 2014. Argos executive management will host a conference ... [Published GlobeNewswire - Mar 14 2014]
First reported Mar 05 2014 - Updated Mar 06 2014 - 1 reports

Argos Therapeutics presents new data from clinical research for AGS-004 patient-specific immunotherapy in HIV treatment

Argos Therapeutics has presented data from clinical studies of AGS-004, the company's patient-specific immunotherapy currently in development for the treatment of HIV infection. ... [Published PBR - News - Mar 05 2014]
First reported Feb 20 2014 - Updated Feb 20 2014 - 3 reports

Forbion Announces Closing of Public Offering of Portfolio Company, Argos Therapeutics

NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics has closed its initial public offering. ... [Published Business Wire Science: Science News - Feb 20 2014]

Quotes

"Our aim in conducting this webinar is to demystify switch testing and take the ‘shade tree’ mechanic out of the equation,” explains Tomalino. “We will illustrate how to automatically and precisely capture the pressure at which your switch should be actuated, instead of waiting for a click and guessing at which point the switch tripped on the pressurepressure gauge dial."
...herapeutics for men's and women's health, today announced that the Company, along with its European commercial partners, is sponsoring a symposium – "A New Paradigm in the Treatment of ED - The Topical Option" – during the European Association of Urology (EAU) Congress...
The company is a Duke University spinout started with help from a $10,000 NCBiotech Business Development Loan in 1998. It’s developing what it calls "breakthrough immunotherapies that target the unique features of a patient's disease."
...to create andexanet alfa as a possible solution," said John T Curnutte, M D , Ph D , executive vice president, research and development at Portola. "The initiation of this new Phase 2 study with edoxaban moves us closer to our goal of bringing andexanet alfa to market as a universal antidote for Factor Xa inhibitors."

More Content

All (56) | News (35) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (8)
sort by: Date | Relevance
ISA and Beamex present web seminar on calibrati... [Published Automation.com - Apr 10 2014]
ISA and Beamex to co-host web seminar on calibr... [Published Process Industry Informer - Apr 09 2014]
Argos Therapeutics, Inc. Announces Filing Of It... [Published BioSpace - Apr 08 2014]
Myriad Submits Premarket Approval to FDA for BR... [Published BioMedReports - Apr 08 2014]
Argos Therapeutics Announces Filing of Its Annu... [Published Noodls - Apr 07 2014]
Argos Therapeutics Announces Filing of Its Annu... [Published GlobeNewswire: Advertising News - Apr 07 2014]
Argos Therapeutics Announces Filing of Its Annu... [Published BusinessWeek - Apr 07 2014]
ARGOS THERAPEUTICS : Announces Filing of Its An... [Published 4 Traders - Apr 07 2014]
Argos Hits $45M IPO [Published North Carolina Biotechnology Center - Apr 05 2014]
#PCTUS: 8 Facts from Day 2 [Published Partnerships in Clinical Trials - Apr 02 2014]
62.81% CAGR Therapeutic Vaccines Market Growth ... [Published PRWeb - Apr 02 2014]
Argos Therapeutics to Present at the 13th Annua... [Published GlobeNewswire: Acquisitions News - Apr 01 2014]
Argos Therapeutics, Inc. Added To Russell 2000®... [Published BioSpace - Apr 01 2014]
Scynexis is poised to be latest Triangle compan... [Published Raleigh News & Observer - Apr 01 2014]
Argos Therapeutics Inc added to Russell 2000(R)... [Published Reuters UK - Mar 31 2014]
ARGOS THERAPEUTICS INC - 10-K - Management's Di... [Published HispanicBusiness.com - Mar 31 2014]
Argos Therapeutics Added to Russell 2000(R) and... [Published GlobeNewswire: Acquisitions News - Mar 31 2014]
Argos Therapeutics, Inc. Reports Fourth Quarter... [Published BioSpace - Mar 28 2014]
Quidel Receives FDA Clearance for Its AmpliVue(... [Published BioMedReports - Mar 28 2014]
Argos Therapeutics Reports Fourth Quarter and Y... [Published GlobeNewswire: Advertising News - Mar 27 2014]
Square 1 Bank takes off on Nasdaq opener [Published Triangle Business Journal - Mar 27 2014]
ARGOS THERAPEUTICS : Assigned Patent [Published 4 Traders - Mar 25 2014]
Argos Therapeutics to Present at 21st Annual Fu... [Published GlobeNewswire: Advertising News - Mar 21 2014]
Argos Therapeutics to Present at 21st Annual Fu... [Published BusinessWeek - Mar 21 2014]
Argos Therapeutics Presents New Data From Clini... [Published Signet Healthcare Partners - Mar 20 2014]
Argos Therapeutics Announces Additional $17.5 M... [Published Signet Healthcare Partners - Mar 20 2014]
Argos Therapeutics To Present Progress Update O... [Published Signet Healthcare Partners - Mar 20 2014]
Exact Sciences Publish Results of DeeP-C Study ... [Published BioMedReports - Mar 20 2014]
Argos Therapeutics to Present at Regenerative M... [Published GlobeNewswire: Government News - Mar 19 2014]
ARGOS THERAPEUTICS : to Present at Regenerative... [Published 4 Traders - Mar 19 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
#PCTUS: 8 Facts from Day 2 [Published Partnerships in Clinical Trials - Apr 02 2014]
Throughout the second day of Partnerships in Clinical Trials , one word was a trending topic throughout the presentations:   communication .   Communication is key among all stakeholders in the clinical trials field to keep trials on a timeline and ...
Argos Therapeutics presents new data from clini... [Published PBR - News - Mar 05 2014]
Argos Therapeutics has presented data from clinical studies of AGS-004, the company's patient-specific immunotherapy currently in development for the treatment of HIV infection. ...
Frontrunning: March 4 [Published Zero Hedge - Mar 04 2014]
Russia Orders Drill Troops Back to Bases (WSJ) Ukraine premier agrees to reforms for aid package ( FT ) Japan Base Wages Rise for First Time in Nearly Two Years ( WSJ ) Only the algos are trading: Citigroup Joins JPMorgan in Seeing Trading-Revenue Drop  ...
Financings of the Fortnight And the Neverending... [Published The IN VIVO Blog - Feb 21 2014]
Somewhere out there, perhaps, is the end of NovImmune's Series B round.More than a year ago, our friends at START-UP examined the fates of biotechs that had reeled in huge private financing rounds. Giant biotech venture rounds are back with a buzz ...
Forbion Announces Closing of Public Offering of... [Published Business Wire Science: Science News - Feb 20 2014]
NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics has closed its initial public offering. ...
1 2 3

Press Releases

sort by: Date | Relevance
Argos Therapeutics Announces Filing of Its Annu... [Published GlobeNewswire: Advertising News - Apr 07 2014]
Argos Therapeutics to Present at the 13th Annua... [Published GlobeNewswire: Acquisitions News - Apr 01 2014]
Argos Therapeutics Added to Russell 2000(R) and... [Published GlobeNewswire: Acquisitions News - Mar 31 2014]
Argos Therapeutics Reports Fourth Quarter and Y... [Published GlobeNewswire: Advertising News - Mar 27 2014]
Argos Therapeutics to Present at 21st Annual Fu... [Published GlobeNewswire: Advertising News - Mar 21 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.